Antoni Ribas
教授
Division of Hematology-Oncology
Department of Medicine, University of California Los Angeles/Jonsson Comprehensive Cancer Center, University of California Los Angeles/Division of Surgical-Oncology, Department of Surgery, University of California Los Angeles/Eli and Edythe Broad Center for Regenerative Medicine and Stem Cell Research, University of California Los Angeles/Department of Molecular and Medical Pharmacology, University of California Los Angeles
关注
立即认领
分享
关注
立即认领
分享
基本信息
浏览量:694
职业迁徙
个人简介
Antoni Ribas, MD, PhD is Professor of Medicine, Professor of Surgery, and Professor of Molecular and Medical Pharmacology at the University of California Los Angeles (UCLA), Director of the Tumor Immunology Program at the Jonsson Comprehensive Cancer Center (JCCC) and the Chair of the Melanoma Committee at SWOG. Trained at the University of Barcelona, with postdoctoral research and clinical fellowships at UCLA. Dr Ribas is a physician-scientist who conducts laboratory and clinical research in malignant melanoma, focusing on gene engineered adoptive cell transfer (ACT) therapies, anti-CTLA4 antibodies, anti-PD-1 antibodies, BRAF and MEK inhibitors and nanoparticle-siRNA.
His NCI, State of California and private foundation-supported research laboratory develops models of disease to test new therapeutic options and studies mechanism of action of treatments in patients. He has been instrumental in the clinical development of several agents approved by the FDA, including pembrolizumab (Keytruda), vemurafenib (Zelboraf), cobimetinib (Cotellic), dabrafenib (Tafinlar) and trametinib (Mekinist). He is an elected member of the American Society of Clinical Investigation (ASCI), the recipient of the AACR Richard and Hinda Rosenthal Award and a National Cancer Institute (NCI) Outstanding Investigator Award.
His NCI, State of California and private foundation-supported research laboratory develops models of disease to test new therapeutic options and studies mechanism of action of treatments in patients. He has been instrumental in the clinical development of several agents approved by the FDA, including pembrolizumab (Keytruda), vemurafenib (Zelboraf), cobimetinib (Cotellic), dabrafenib (Tafinlar) and trametinib (Mekinist). He is an elected member of the American Society of Clinical Investigation (ASCI), the recipient of the AACR Richard and Hinda Rosenthal Award and a National Cancer Institute (NCI) Outstanding Investigator Award.
研究兴趣
论文共 1208 篇作者统计合作学者相似作者
按年份排序按引用量排序主题筛选期刊级别筛选合作者筛选合作机构筛选
时间
引用量
主题
期刊级别
合作者
合作机构
Ameya Champhekar,Rachel Heymans,Justin Saco, Guillem Turon Font,Cynthia Gonzalez,Anne Gao, John Pham, June Lee, Ryan Maryoung,Egmidio Medina,Katie M. Campbell,Daniel Karin,
Sameeha Jilani,Justin D. Saco, Edurne Mugarza, Aleida Pujol-Morcillo, Jeffrey Chokry,Clement Ng,Gabriel Abril-Rodriguez, David Berger-Manerio, Ami Pant, Jane Hu, Rubi Gupta,Agustin Vega-Crespo,
Nature Communicationsno. 1 (2024): 1-19
EUROPEAN JOURNAL OF CANCER (2024): 113505-113505
Ameya Champhekar,Rachel Heymans,Justin Saco, Guillem Turon Font,Cynthia Gonzalez,Anne Gao, John Pham, June Lee, Ryan Maryoung,Egmidio Medina,Katie M. Campbell,Daniel Karin,
Molecular Cancerno. 1 (2024): 1-1
Proceedings of the National Academy of Sciences of the United States of Americano. 21 (2023)
crossref(2023)
JOURNAL OF CLINICAL ONCOLOGYno. 16 (2023)
引用0浏览0引用
0
0
Jana Biermann, Yiping Wang, Linyue Fan,Patricia Ho, Amit D. Amin,Johannes C. Melms,Somnath Tagore, Kevin Hoffer-Hawlik,Parin Shah, Neha Shaikh, Priyanka Ramaradj,Mingxuan Zhang,
CANCER RESEARCHno. 7 (2023)
引用0浏览0引用
0
0
加载更多
作者统计
合作学者
合作机构
D-Core
- 合作者
- 学生
- 导师
数据免责声明
页面数据均来自互联网公开来源、合作出版商和通过AI技术自动分析结果,我们不对页面数据的有效性、准确性、正确性、可靠性、完整性和及时性做出任何承诺和保证。若有疑问,可以通过电子邮件方式联系我们:report@aminer.cn